[Complex karyotype abnormalities in pediatric acute myeloid leukemia].

Area of Science:

• Hematology
• Cytogenetics
• Pediatric Oncology

Background:

• Limited data exists on the prognostic significance of chromosome changes in pediatric acute myeloid leukemia (AML).
• The prognostic value of complex karyotypes (≥3 unrelated abnormalities) in pediatric AML requires clarification.
• Most existing data on complex karyotypes originates from adult AML studies.

Purpose of the Study:

• To investigate the characteristic features of complex karyotypes in newly diagnosed pediatric AML.
• To compare complex karyotype characteristics between pediatric and adult AML.
• To identify age-related patterns in complex karyotype frequency in pediatric AML.

Main Methods:

• Analysis of karyotypes from 254 newly diagnosed pediatric AML patients (0-15 years) before therapy.
• Classification of complex karyotypes based on the presence or absence of favorable chromosome abnormalities (t(8;21), t(15;17), inv(16)).
• Comparison of complex karyotype features between pediatric and adult AML cohorts.

Main Results:

• Complex karyotypes were identified in 13.8% (35/254) of pediatric AML patients.
• Pediatric AML with complex karyotypes showed a significantly lower frequency of adverse risk markers (30%) compared to adult AML (76%).
• The highest incidence of complex karyotypes was observed in children aged 0-3 years, a novel finding.

Conclusions:

• Complex karyotypes in pediatric AML exhibit distinct features compared to adult AML, particularly regarding adverse risk markers.
• The high frequency of complex karyotypes in very young children (0-3 years) warrants further investigation.
• Understanding these pediatric-specific complex karyotype characteristics is vital for refining AML pathogenesis models and therapeutic strategies.